Abbott's Chagas disease screening test approved in US
This article was originally published in Clinica
Executive Summary
The US FDA has approved Abbott's blood screening test for Trypansoma cruzi via a biologic licence application (BLA). The firm claims the Abbott Prism Chagas is the first fully automated blood test for the parasite, which causes Chagas disease. Symptoms of the disorder, which is mainly found in Central and South America, include heart disease and gastrointestinal malformations, and it can be fatal if left untreated. Around 8-11 million people are infected worldwide, according to the US Centers for Disease Control and Prevention. Blood centres in the US started screening for antibodies to T cruzi in 2007 to minimise transmission of the disease. Abbott's test, an in vitro chemiluminescent immunoassay, is not intended for diagnosing Chagas infection.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.